Latest News and Press Releases

KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer’s disease agitation and...

Entrada Therapeutics announces positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-44-201 clinical study.

Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at...

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Phase 1 clinical trial of SL-325 enrollment complete; data expected in the second quarter of 2026 –Phase 2 clinical trial of SL-325 in patients with Crohn’s disease expected to initiate in the third...

KT-579 demonstrated activity comparable or superior to approved and clinically active therapies in preclinical IBD models KT-579 Phase 1 healthy volunteer trial ongoing, with data expected in 2H26 ...

-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed...

Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with...

Laudio and ASHHRA report shows how frontline leadership and “Leader Standard Work” improve healthcare workforce stability and retention.

Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and...